कंपनी का अवलोकन
Zepp Health Corporation operates globally as a prominent entity within the technology sector, specifically focusing on the consumer electronics industry by developing smart wearables and health technology solutions. The organization empowers individuals to optimize their health, fitness, and wellness journeys through its distinct consumer brands, which include Amazfit, Zepp Clarity, and Zepp Aura, utilizing proprietary digital health platforms. As of the latest reported data, the company possesses a market capitalization of $168.48M, while its trailing twelve-month revenue stands at $258.90M. The employee count is currently listed as N/A in available public filings, indicating a need to rely on revenue and market cap metrics to gauge operational scale. These valuation figures suggest that the market values the company's proprietary technology and brand portfolio at a relatively modest scale compared to large-cap technology peers, reflecting its position as a mid-sized player in the expanding wearable health device market.
वित्तीय स्वास्थ्य
Zepp Health Corporation reported a total revenue of $258.90M over the trailing twelve months, yet it simultaneously recorded a net income loss of $-40,068,000 and an EBITDA of $-24,213,000, highlighting a significant divergence between top-line sales and bottom-line profitability. The substantial gap between the $258.90M in revenue and the negative $40.07M in net income reveals a cost structure where operating expenses and cost of goods sold are consuming a majority of generated sales, preventing the realization of profit at the current scale. While the free cash flow figure is listed as N/A, the presence of $57.05M in cash reserves against $116.31M in total debt indicates a leverage-heavy financial position rather than abundant liquidity for immediate expansion without raising capital. The gross margin stands at 38.3%, which suggests reasonable efficiency in production and supply chain management, yet the operating margin of -4.5% and the profit margin of -15.5% indicate that high operational costs are eroding earnings before interest, taxes, and non-operating items. Comparing the total cash of $57.05M to the total debt of $116.31M, the balance sheet appears highly leveraged, a stance typical for growth-stage technology firms but one that requires careful monitoring of interest coverage and refinancing risks. The debt-to-equity ratio of 54.21 further underscores this leveraged structure, implying that a significant portion of the company's assets is financed through creditor obligations rather than shareholder equity. Additionally, the current ratio of 1.02 suggests that the company's short-term assets barely exceed its short-term liabilities, pointing to tight liquidity constraints that could limit flexibility in meeting immediate obligations. Finally, the return on equity is -17.2% and the return on assets is -3.3%, metrics that collectively reveal that management's current strategies are not generating positive returns on the capital invested by shareholders or the asset base, signaling a period of reinvestment or strategic transition rather than value creation.
मूल्यांकन आकलन
The valuation metrics for Zepp Health Corporation present a complex picture, as the P/E Ratio (TTM) is N/A due to negative earnings, while the forward P/E is listed at -1152.00, a figure that mathematically reflects the market's pricing in anticipated future earnings recovery rather than current profitability. The price-to-book ratio of 0.85 indicates that the market is currently valuing the company at a discount to its book value, suggesting a lack of market premium over the tangible assets recorded on the balance sheet. Alternative valuation multiples such as the price-to-sales ratio of 0.65 and the EV/EBITDA of -123.31 provide additional context, implying that investors are pricing the stock based on revenue generation potential and enterprise value relative to negative earnings power rather than current cash flow yields. The stock's price volatility is evident when observing the 52-week high of $61.85 and the 52-week low of $2.12, a massive range that suggests extreme price instability; without a specific current price provided in the facts, the trading range itself highlights the speculative nature of the security. The beta value of 1.77 further quantifies this risk profile, indicating that the stock's price is expected to be significantly more volatile than the broader market, moving approximately 77% more than the market index during periods of fluctuation.
Growth & Income
Zepp Health Corporation has demonstrated robust top-line expansion with a revenue growth rate of 43.0% year-over-year, whereas the earnings growth rate is N/A due to the company's continued net losses. This divergence implies that while the company is successfully capturing market share and increasing sales volume, profitability has not yet scaled proportionally with revenue, a common characteristic in the early stages of technology product lifecycles. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. Instead of paying out earnings, the company follows a growth-oriented capital allocation strategy where all available cash is likely directed toward research and development, manufacturing expansion, and debt reduction. This reinvestment approach is necessary given the negative return metrics, as generating cash flow to fund operations and growth internally is prioritized over income generation for investors. Overall, the growth and income profile of Zepp Health Corporation is defined by aggressive revenue expansion coupled with significant financial losses and a complete absence of dividend distribution, reflecting a high-risk, high-potential-growth investment thesis focused on future profitability realization.